BioCentury
ARTICLE | Company News

Aspen, GlaxoSmithKline sales and marketing update

August 27, 2012 7:00 AM UTC

GlaxoSmithKline will divest 25 non-promoted and generic products in Australia to Aspen's Aspen Global Inc. subsidiary for about £172 million ($270.2 million) in cash. Products include antiviral drug Valtrex valacyclovir; neurology drug Lamictal lamotrigine; antibiotic Amoxil amoxicillin; and antidepressant Aropax paroxetine. GSK said the divested brands generated sales of about £83 million ($128.9 million) in 2011 and about £31 million ($48.5 million) in 1H12. The deal is expected to close next quarter. ...